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Abstract
Two major breast cancer sub-types are defined by the expression of estrogen receptors on tumour cells. Cancers with large
numbers of receptors are termed estrogen receptor positive and those with few are estrogen receptor negative. Using
genome-wide single nucleotide polymorphism genotype data for a sample of early-onset breast cancer patients we
developed a Support Vector Machine (SVM) classifier from 200 germline variants associated with estrogen receptor status
(p,0.0005). Using a linear kernel Support Vector Machine, we achieved classification accuracy exceeding 93%. The model
indicates that polygenic variation in more than 100 genes is likely to underlie the estrogen receptor phenotype in early-
onset breast cancer. Functional classification of the genes involved identifies enrichment of functions linked to the immune
system, which is consistent with the current understanding of the biological role of estrogen receptors in breast cancer.
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Introduction
Breast cancer sub-types may be classified according to the
number of estrogen receptors present on the tumour. Tumours
expressing large numbers of receptors are termed estrogen
receptor positive (ER+) and, conversely, estrogen receptor negative
(ER2) for few or no receptors. ER status is extremely important
since ER+ cancers grow under the influence of estrogen, and may
therefore respond well to hormone suppression treatments, while
the proliferation of ER2 cancers is not driven by estrogen and
does not respond to estrogen modulation. Deroo and Korach [1]
describe the ‘‘classical’’ (or genomic) pathway of estrogen action:
an estrogen molecule binds to a receptor which induces receptor
phosphorylation and dimerization to form a nuclear estrogen-ER
complex [1,2]. The transcription of target estrogen responsive
genes is regulated through the binding of the estrogen-ER complex
to specific estrogen response elements (EREs) located in the gene
promoter region [3]. The target genes of this pathway are many
and varied; the majority are crucial for normal cell physiology,
growth and differentiation and can promote the growth of breast
tumours under certain conditions [2,4].
Two hypotheses seek to explain the relationship between
estrogen and breast cancer. The first considers the proliferation
of mammary cells stimulated by the binding of estrogen to the ER
leading to an increase in the number of target cells and associated
elevated risk for replication errors and acquisition of deleterious
mutations during cell division and DNA replication. A second
hypothesis identifies genotoxic by-products of estrogen metabolism
which may lead to DNA damage and, subsequently, cancer.
Evidence exists to support both hypotheses as mechanisms to
initiate and promote tumour development [1]. Estrogen is
necessary for breast tumour formation regardless of the receptor
status of the cells and the tumour-promoting effects of estrogen are
not limited to ER+ cells alone [5]. While estrogen influences the
growth of ER+ tumour cells through binding receptors it is
suggested that the growth of ER2 tumour cells is the result of
estrogen acting on cells of the tumour microenvironment which
enhances angiogenesis, stromal cell recruitment and thus, tumour
development and progression [5,6].
The estrogen receptor has two forms, a and b, which are
encoded by the ESR1 and ESR2 genes respectively. The two forms
have distinct roles in breast tissue; ERa promotes cell proliferation
in response to estrogen while ERb inhibits proliferation and
tumour formation [7,8]. Single nucleotide polymorphisms (SNPs)
in the ESR1 gene have been associated with increased suscepti-
bility to breast cancer, however they are fairly rare [9–11].
Variation in the ESR2 gene may also be important in disease
susceptibility however, no SNPs demonstrating a strong associa-
tion with breast cancer risk have been identified [1,12,13]. A
number of SNPs have been identified through genome wide
association studies (GWAS) as being breast cancer risk SNPs. In
many cases these SNPs relate to the risk of developing a particular
subtype of disease, often the ER+ type [14]. Overall, the genetic
basis of the estrogen receptor cancer sub-types is not well
understood and worthy of further analysis [1].
We hypothesized that patients who develop ER+ and ER2
tumours would show distinct constitutional genetic profiles the
exploration of which could yield new insights into the biological
effect of the host genomic environment on the emergence of these
forms of breast cancer. We developed machine learning (ML)
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classifiers to explore the distinction between profiles in well
characterised breast cancer cases. ML is used extensively in many
scientific fields for classification purposes. ML methods have been
used in genetic studies to explore the underlying genetic profile of
disease and build models capable of (i) detecting gene-gene
interactions; (ii) predicting disease susceptibility; (iii) predicting
cancer recurrence; and (iv) predicting cancer survivability [15].
Genetic SNP data can be used to build such classification models,
with high accuracy observed in many cases. Support Vector
Machines (SVMs) have been shown to have excellent power and
the ability to establish binary classification based on multiple
features [16]. The aim of the SVM approach is to separate the
data points from the two classification groups using a decision
surface, called a hyperplane. The simplest classifier is a linear
hyperplane but, for more complex datasets, it is necessary to map
the input features into high-dimensional space using a non-linear
mapping function, called a kernel function [16]. The placing of the
separating hyperplane depends on maximising the margin
between the hyperplane and the data points of two classes. If
the input data are not cleanly separable by a hyperplane (a non-
separable case, [17]), it is desirable to separate the data by the
smallest sum of all classification errors: the ‘soft margin
hyperplane’. In the case of genetic data linear models may be
sufficient in the absence of, for example, complex underlying gene-
gene interactions whilst kernel functions are most applicable
otherwise. We develop here a SVM classifier which discriminates
ER+ and ER2 breast cancer cases which provides new insights
into the biological nature of the ER+/ER2 breast cancer sub-
division.
Results
SVM classification accuracy
The overall classification accuracy of a ML classifier is a
measure of how successful the method is at assigning samples to
the correct class. In this study the highest classification accuracy
was achieved using 200 SNPs fully genotyped in all 542 study
samples (Table S1) and individually associated with the ER-
negative phenotype (p,0.0005). Five kernel models were pro-
duced, all with classification accuracy exceeding 93% (Table 1).
Classification accuracy was reduced when the highest ranked 50
(,86%) and 100 (,93%) SNPs were considered (Table S2). The
highest classification accuracy was achieved using the radial basis
function (RBF) kernel and normalized quadratic polynomial
kernel: 95.95% and 95.69% respectively. In both cases 99% of
the ER2 cases and 89% of the ER+ cases were classified correctly.
The true positive rate (number of ER+ cases correctly classified)
was equal in all five models, demonstrating that they are equally
successful at recognising and classifying ER+ cases in the test data.
The true negative rate always exceeds 0.95, indicating that at least
95% of ER2 cases are classified correctly in each model. All
models are superior at classifying ER2 cases compared to ER+
cases.
Classifier performance was further evaluated using the receiver
operating characteristic (ROC) area under curve (AUC) values
which indicate these models have excellent accuracy: all exceed
0.9 (Table 1). ROC curves were produced for the linear model and
RBF kernel model for both ER+ and ER2 cases (Figure 1) based
on true and false positive/negative values. Figure 2 shows the
relationship between chi-squares for individual SNPs derived from
PLINK [18,19] and weights from the linear classification model.
Variants with the largest (absolute value) weights are the most
discriminating in the classifier. The input chi-squares used in
feature selection (see methods) are uncorrelated with the linear
SVM model weights (r =20.026).
SVM classifiers were produced for two additional subsets of
SNP features to further investigate classification accuracy. A set of
200 SNPs showing no individual association for the ER+/ER2
distinction and a subset of 200 randomly selected SNPs were used
to produce classification models (Table S3). Accuracy is low for
both subsets (,69%) as are true positive rates in both cases
(,33%). Area under ROC curve values are also very low at 0.51
or less, indicating that these models perform no better than
‘random’ which achieves an AUC of 0.5.
DAVID functional annotation
To identify biological terms and pathways that are particularly
enriched for genes represented in the classifier (Table S1) we used
the DAVID annotation tool [20–22] DAVID identified four gene
annotation clusters, three enriched pathways and 36 term
annotation clusters. Of these, two gene annotation clusters and 9
term annotation clusters are particularly enriched (enrichment
score $1.00) relative to the whole genome background. The
cluster with the highest enrichment score contains genes related to
the inflammatory response (Table 2) and the next highest (Table 3)
shows enrichment of genes in specific pathways related to axon
guidance and signalling.
DAVID analysis was also performed for the 100 SNPs with the
highest absolute classifier weights (Table S1) from the linear SVM
kernel model. Similar annotation clusters were identified (data not
shown) with functions relating to immune cell activation again
being particularly enriched in the gene set.
Discussion
Machine learning techniques have an important role to play in
disease classification and the discovery of underlying disease
mechanisms, including gene-gene interactions or signalling path-
Table 1. Weka kernels and classification results using 200 SNPs with the strongest ER+/2 association.
Kernel type
Percentage correctly
classified
True positive
rate
False positive
rate
True negative
rate
False negative
rate Area under ROC
Linear 93.2863.07 0.8860.07 0.0460.03 0.9660.03 0.1260.07 0.9260.04
Normalized quadratic
polynomial
95.6962.69 0.8960.08 0.0160.02 0.9960.02 0.1160.08 0.9460.04
Quadratic Polynomial 93.8963.06 0.8960.07 0.0460.03 0.9660.03 0.1160.07 0.9360.04
Cubic Polynomial 94.5462.94 0.8960.07 0.0360.03 0.9760.03 0.1160.07 0.9360.04
RBF 95.9562.61 0.8960.07 0.0160.02 0.9960.02 0.1160.07 0.9460.04
doi:10.1371/journal.pone.0068606.t001
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Figure 1. ROC curves for ER+ and ER2 classification using linear and RBF kernels. ROC curves and area under ROC curve (AUC) values can
be used as more robust measures of classifier accuracy beyond overall classification accuracy. (A) ROC curves for ER+ classification. (B) ROC curves for
ER2 classification. In both cases the linear model is represented by a dashed line and the RBF kernel model is represented by a solid line. The point
on each curve corresponds to the true positive/negative and false positive/negative values obtained from 100 iterations of 10-fold cross-validation
carried out on 542 samples with 200 SNP features. The ROC curve for any meaningful classifier needs to lie above the y = x line; the case where equal
proportions of cases would be classified correctly and incorrectly, as would occur if class values were assigned at random.
doi:10.1371/journal.pone.0068606.g001
Figure 2. Relationship between weights under a linear classifier and chi-square values used in feature selection. SVM models were
constructed on 542 study samples with genotype data for a subset of 200 SNPs chosen based on ER+/2 association, determined from the chi-square
statistic. SNP feature weights were obtained from the linear SVM model and used as an indicator of the importance of each feature for classification;
SNPs with the largest absolute weight values are the most important for classification. Chi-square values used in feature selection and SVM classifier
weight values are uncorrelated; Pearson’s correlation coefficient r =20.026. SNPs with absolute weight values . 0.5 are annotated with the name of
the gene in which they reside or are in closest proximity to.
doi:10.1371/journal.pone.0068606.g002
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way enrichment which influences disease. Support vector
machines in particular are state-of-the-art classifiers [23] with
documented success at building accurate classifiers for disease
versus control populations based on genetic data [24–26]. As
discussed here, SVMs are useful for the analysis of disease sub-
types given that many diseases (breast cancer included) comprise
distinct sub-types with individual biology. The best resultant SVM
model for ER+/ER2 status in early-onset breast cancer cases
successfully classifies cases into sub-types with ,96% accuracy
(Table 1), with accuracy exceeding 93% with all kernels.
Although SVM classification accuracy is an important indicator
of success it can be misleading, particularly in the case of an
unbalanced data set (unequal numbers of cases in the two groups),
as in this study [27]. Other indicators, such as the number of cases
correctly classified into each group and the area under ROC curve
(AUC) values should also be considered. A ML algorithm may
produce a majority-class classifier when presented with an
unbalanced dataset [27]. In this situation all cases are classified
as members of the majority class, making the classifier appear
more accurate than in reality. For example, using this dataset, an
accuracy of 68.6% can be achieved by simply classifying all 542
samples into the majority group: ER2, giving a misleading
impression that the classifier is correctly identifying a reasonable
proportion of the samples. However, the true positive and true
negative rates, 0.00 and 1.00 respectively, identify the model as
invalid. The true positive (number of true ER+ cases classified as
ER+; TPR ,89%) and true negative (number of true ER2 cases
classified as ER2; TNR ,99%) results from the models in this
study (Table 1) indicate that a substantial proportion of the ER+
and ER2 cases are correctly classified. Therefore it is reasonable
to conclude that the SVM models produced are successful as
ER+/ER2 classifiers and any one of the five models is suitable as
a classifier for unseen data. It is evident however that the ER2
cases are classified more accurately than ER+ cases, which is likely
to reflect the unbalanced data (372 ER2 cases versus 170 ER+
cases). The greater difficulty in classifying ER+ cases arises from
the more limited variation in the SNP profile given the smaller
number of cases available to the classifier.
Classifier performance can be further evaluated using receiver
operator characteristic (ROC) curves which are based on the true
positive and true negative rates at several different thresholds. One
of the major advantages of the ROC curve is that it is unaffected
by unbalanced datasets [28]. The area under ROC curve (AUC)
measure [29] takes values between 0.00 and 1.00 with values
closer to 1.00 indicating good performance. A random classifica-
tion would produce an AUC of 0.5, the AUC values for the ER+/
ER2 classifier (Table 1) are in the range 0.92–0.94, suggesting
excellent classification ability.
Feature selection is an important component of building a ML
classifier. Much of the SNP data in these samples will not be useful
for building an accurate model (Table S3) so it was necessary to
select a subset of SNP features from which to build a classifier. For
a review on feature selection methods available for ML algorithms
see [30]. Feature selection prior to SVM implementation is
essential to avoid the ‘curse of dimensionality’, which tends to arise
Table 2. DAVID Annotation Clusters: Enriched gene ontology (GO) terms from the ER+/2 classification.
Cluster 1: Enrichment Score: 1.97 (GO: Biological Process)
Term No. genes % genes P value Fold Enrichment
calcium ion transport 7 6.03 0.00018 8.34
T cell proliferation 4 3.45 0.00051 25.05
di-, tri-valent inorganic cation transport 7 6.03 0.00056 6.73
T cell activation 6 5.17 0.00084 8.05
lymphocyte proliferation 4 3.45 0.00187 16.10
leukocyte proliferation 4 3.45 0.00214 15.37
mononuclear cell proliferation 4 3.45 0.00214 15.37
lymphocyte activation 6 5.17 0.00613 5.09
positive regulation of immune system process 6 5.17 0.01269 4.26
leukocyte activation 6 5.17 0.01356 4.19
cell proliferation 8 6.90 0.01360 3.10
response to abiotic stimulus 7 6.03 0.02048 3.22
cell activation 6 5.17 0.02619 3.54
Cluster 2: Enrichment Score: 1.93 (GO: Cellular Component)
Term No. genes % genes P value Fold Enrichment
synapse 10 6.90 0.00024 4.50
cell junction 11 9.48 0.00128 3.39
doi:10.1371/journal.pone.0068606.t002
Table 3. Significant enrichment of genes in KEGG pathway
identified by DAVID.
Pathway Genes P value
Axon guidance EPHA4, FYN, NRP1, NTN4, PPP3CA 0.007
T cell receptor signalling
pathway
FYN, IL5, PPP3CA, PTPRC 0.027
Fc epsilon RI signalling
pathway
FYN, IL5, MAP2K4 0.081
doi:10.1371/journal.pone.0068606.t003
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from training of too few examples with too many variables [15].
Therefore, it is suggested that the sample-to-feature ratio should
ideally exceed 5:1, which is clearly not achievable with unselected
genome-wide SNP data. Machine learning theory considers the
concept of VC-dimension [31]. The VC-dimension quantifies a
learning machine’s capacity describing how complex a model can
be: learning machine functions with high capacity may generate
lower training error rates but require larger training sets than
simpler, low capacity models. The best theoretical performance
guarantee is achieved through the right balance between the
accuracy attained for a given training set and the model capacity.
Because analysis of genomic disease data considers potentially very
large number of features (SNPs) evaluated on relatively small
numbers of samples (genomes) feature selection strategies aim to
reduce overfitting. Alternatives to the approach to reduce feature
complexity adopted here include Recursive Feature Elimination
(RFE) applied to linear SVMs using the ranked SVM weights to
recursively eliminate features [32]. Such an approach has been
used extensively for DNA micro-array gene expression data but
has received less attention thus far for GWAS disease data.
The underlying biological nature of the genes identified as
discriminators of ER+/ER2 breast cancer was of particular
interest in this study. To identify gene enrichment in gene groups
and pathways we used the DAVID toolset. Analysis of the 139
genes that the classifier SNPs reside in, or are closest to, identified
gene groups, pathways and annotation terms that were particu-
larly enriched (Tables 2 and 3). Of the two annotation clusters with
the highest enrichment scores (Table 2) it is notable that cluster 1
contains genes relating to immune/inflammatory cell activation,
differentiation and proliferation. This suggests one of the
distinctions between ER+ and ER2 tumours relates to genetic
variation in immune system pathways. The role of the immune/
inflammatory response in influencing tumourigenesis and tumour
progression, through the formation of an inflammatory microen-
vironment at the tumour site, is well characterised [33–36]. It has
been suggested that as much as 50% of breast tumour volume
comprises cells of the immune system, in particular, tumour-
associated macrophages (TAMs) and tumour-infiltrating lympho-
cytes (TILs) [37] that establish the tumour microenvironment.
Infiltrating immune cells are likely to be a major source of pro-
tumourigenic factors at the tumour site because they have the
capacity to release cytokines, chemokines, metalloproteases,
reactive oxygen species and a number of bioactive mediators into
the stroma. Furthermore, infiltrating immune cells regulate a
number of processes, including enhanced cell survival, angiogen-
esis and suppression of anti-tumour immune responses [38]
suggesting a role in both tumour development and progression.
In particular, TAMs have been implicated as a source of mitogenic
signals for tumour cells through cytokine secretion [39] potentially
enhancing cell division and tumour growth.
The role of estrogen and estrogen receptors as regulators of
proliferation and differentiation in breast tissue is well-established
and is crucially important for disease progression in many cases
[34,40]. It has been suggested that infiltrating leukocytes are a
major source of estrogen expression in breast tumours [41] which
could contribute to disease development and progression.
The estrogen receptor status of breast cancer patients has long
been recognised as a strong prognostic factor that influences
patient treatment options and survival. Patients with ER2 forms
of the disease tend to show decreased survival rates in the first few
years after diagnosis and present with more aggressive tumours
[42–45]. However, after 10 years of disease-free survival a relapse
is more likely to occur in a patient who originally presented with
ER+ disease [45]. A number of other factors influence breast
cancer patient survival, one of which is the infiltrating immune
system cells. There is a suggested strong correlation between the
infiltration of lymphocytic cells and patient survival, particularly in
patients with disease onset before the age of 40 years [33]. The
number of CD8+ T lymphocytes present at the tumour site
influences patient survival, with higher numbers being associated
with better survival rates. This effect is more evident in patients
presenting with ER2 tumours compared to ER+ tumours [46]. In
contrast, TAM levels in breast tumours appear to positively
correlate with aggressiveness of disease and poor prognosis
[47,48].
DAVID analysis of the gene set also identified five genes
implicated in the ‘axon guidance’ pathway (Table 3). Axon
guidance molecules are important in the mammary gland for
maintaining normal cell proliferation and adhesion during tissue
development [49] and the proximity of nerves and blood vessels in
a number of tissues suggests that there may be molecular cross-talk
and common cues between these structures [50]. Dysregulation of
these guidance molecules in the mammary gland has been linked
to breast cancer initiation and progression [49].
Genome wide association studies have identified risk-related
SNPs for many diseases. Thirty-five SNPs, which lie in or near to
36 genes, are identified as breast cancer risk SNPs in the Catalog
of Published Genome-Wide Association Studies [51]. From the
SNPs used in the ER+/ER2 classifier none of the 35 risk SNPs is
present in this list nor are any of the classifier SNPs in or near the
36 catalogued genes. Thus, the SNPs identified in this study
represent a set of genes not previously linked to breast cancer risk
although some of the genes have been linked to roles in prognosis.
Our analysis finds that variation in, or near, at least 139 genes
defines the genetic background on which different estrogen
receptor tumour phenotypes are most likely to arise in early onset
breast cancer patients. The polygenic nature of complex
phenotypes has become an emerging theme from the numerous
genome-wide association studies which have identified a large
number of causal variants with minor impacts on risk. A polygenic
model seems appropriate to define the distinction between breast
cancer sub-types such as ER+/ER2, which are likely to represent
distinct forms of disease. The evidence that this distinction relates
in part to genetic variation in highly complex immune system
pathways reinforces the emerging concept that the presenting
cancer phenotype is shaped not only by a random series of
acquired somatic gene mutations but also by the stable genetic
background of the individual in whom the cancer arises.
Understanding interactions between the host genome and the
process of oncogenesis will be an important contribution to the
development of more individualised treatment and prevention
approaches in the future.
Materials and Methods
Breast cancer samples
542 early-onset breast cancer patients were selected from the
‘Prospective study of Outcome in Sporadic versus Hereditary
breast cancer’ (POSH) cohort [52] of ,3000 patients with disease
onset before the age of 40 years. Germline DNA samples were
genotyped for 490,732 SNPs spanning chromosomes 1 to 22.
Tumours from all cases were classified for estrogen receptor status
with 170 identified as ER+ and 372 as ER2. The POSH study
received approval from the South and West Multi-centre Research
Ethics Committee (MREC 00/6/69). Written consent was given
by the patients for their information to be stored in the hospital
database and used for research.
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SNP genotyping
Genotyping of the breast cancer samples was conducted using
the Illumina 660-Quad SNP array. Genotyping was conducted at
the Mayo Clinic, Rochester, Minnesota, USA (261 samples), and
the Genome Institute of Singapore, National University of
Singapore (281 samples) [53]. To ensure complete harmonisation
of genotype calling, the intensity data available from both
locations, in form of .idat files, were combined and used to
generate genotypes using the algorithm in the genotyping module
of Illumina’s Genome Studio software. A GenCall threshold of
0.15 was selected and the HumanHap660 annotation file was
used. SNPs were excluded from further analysis if they had a
sample minor allele frequency (MAF) below 0.01, a genotyping
call rate ,95% or showed significant deviation from Hardy-
Weinberg equilibrium (HWE, P-value ,0.0001). We used the
pairwise Identity-By-State (IBS) and multidimensional scaling,
implemented in PLINK v1.07 [18,19], to confirm that patients
were ethnically homogeneous. A proportion of the SNPs had
missing genotypes and we used the MACH 1.0 program [54–56]
to impute missing genotypes, where possible, based on genotype
and haplotype phase data specific for CEU population available
from HapMap phase 2 project. Genotype imputation was used to
establish a set of SNPs with complete genotypes for testing as
features in the models. However, imputation failed to resolve all
genotypes for 27 SNPs with high chi-squares and these were
removed from further consideration in the SVM models and
replaced with the next most associated and fully genotyped SNPs
in the ranked list.
SNP feature selection
SNPs showing significant association with ER2 cases were
identified from the additive chi-squared association test imple-
mented in the PLINK toolset in which ER+ samples were labelled
as ‘controls’ and ER2 samples were labelled as ‘cases’. Based on
results from the chi-squared test all SNPs were ranked in terms of
association with the ER+/2 classification. Subsets of SNPs were
selected as features for SVM models from the ranked list of SNPs
and models were produced from subsets of 50, 100 and 200 SNPs
to test utility as discriminatory factors for ER+/ER2 breast
cancer.
SVM model input
The three genotypes at each SNP were converted into numeric
values following [24] and [25]. Major and minor allele frequencies
for each SNP were determined from all genotypes in the sample.
Heterozygous genotypes were labelled 0, homozygotes for the
major allele were labelled 1, and homozygotes for the minor allele
labelled 21. The two classes of samples in the models were ER+
cases and ER2 cases.
Building a support vector machine classifier
Support vector machines are supervised machine learning
algorithms which build models based on ‘training’ data and search
for similar patterns in ‘test’ data [16]. The training set is often a
subset of all samples complete with all class and feature values and
the resultant model is then applied to the remaining test data.
Novel data can be presented to the model and classified according
to the position of the data point relative to the hyperplane
constructed from the training set. The robustness and reliability of
the SVM classifier can be tested using cross-validation, where the
data is split into n equally sized sets testing n models. We used 10-
fold cross-validation: data were divided into 10 approximately
equal-sized sets and a classifier built based on the data in 9/10 of
these sets. The remaining 10% of data was used as a test set to
determine the accuracy of the classifier. This process was repeated
10 times with each set representing the test data once and average
classification accuracy determined. We further explored 10-fold
cross-validation using 100 replicates and mean accuracy from
1000 resultant models was obtained for alternative kernel models.
The SVM classification model was produced using the Weka
data mining software [57,58]. The Sequential Minimal Optimi-
zation (SMO) algorithm for training a SVM classifier was applied
to the data. Five kernel models were evaluated; linear, normalized
quadratic polynomial, quadratic polynomial, cubic polynomial,
and radial basis function (RBF).
Gene annotation
Annotation of sets of SNPs used in the classification models was
undertaken using the ANNOVAR software [59,60]. Gene-based
annotation was carried out using the UCSC ‘Known Gene’
database. SNPs were annotated as intergenic, exonic, intronic,
downstream, ncRNA intronic, ncRNA exonic, upstream, UTR3,
or UTR5. For SNPs situated outside genes the closest gene was
identified and gene names were taken from the HUGO Gene
Nomenclature Committee database [61,62]. A total of 139 unique
gene names were linked to the set of 200 SNPs used in the final
classifier (Table S1).
Functional gene classification
Functional gene annotation clusters were identified using the
‘Gene Functional Classification’ tool in DAVID (Database for
Annotation, Visualization and Integrated Discovery) [20–22].
DAVID determines significant enrichment of function within a
submitted gene name list by contrasting with a ‘whole genome’
background. Annotation clusters were identified from the 139
genes using the ‘Functional Annotation Clustering’ tool and five
annotation categories: disease, functional categories, gene ontol-
ogy, pathways and protein domains. Enriched pathways were
identified using only the ‘Pathways’ annotation category with
BBID, BIOCARTA, and KEGG selected.
Supporting Information
Table S1 200 SNPs which most strongly discriminate
ER+ and ER2 breast cancers used in the classification
models. The weights are taken from a linear model built using
one iteration of 10-fold cross-validation in the WEKA Explorer.
Classification accuracy for this model was 92.4%. The magnitude
of the absolute values of the SNP weights indicates importance of
the SNP for classifying cases. Positive SNP weights relate to
classifying ER+ cases while negative SNP weights relate to
classifying ER2 cases. For those SNPs that are not located within
a gene the nearest gene is given and the distance of the SNP from
this gene is indicated by dist = .
(DOCX)
Table S2 Weka kernels and classification results for 100
and 50 SNPs with highest chi-squares. Comparison of
classifiers built with 100 and 50 highest ranked SNPs from PLINK
chi-square test.
(DOCX)
Table S3 Weka kernels and classification results for
bottom 200 and random 200 SNPs. Comparison of classifiers
built with 200 random SNPs and the lowest ranked by PLINK chi-
square test.
(DOCX)
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